DALY II USA/ MB-CART2019.1 for DLBCL

NCT04792489 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

248

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Relapsed Diffuse Large B Cell Lymphoma
High Grade B-cell Lymphoma (HGBCL)
Primary Mediastinal B-cell Lymphoma (PMBCL)
Transformed Lymphoma
Central Nervous System Lymphoma
Mantle Cell Lymphoma (MCL)
Richter Transformation

Interventions

BIOLOGICAL: zamtocabtagene autoleucel (MB-CART2019.1)
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Bendamustine

Sponsor

Miltenyi Biomedicine GmbH